How should Auvelity (dextromethorphan‑bupropion) be initiated, dosed, and monitored in adults with major depressive disorder who have not responded to other antidepressants?

Auvelity (Dextromethorphan-Bupropion) for Major Depressive Disorder

Initiation and Dosing

Start Auvelity at one tablet (45 mg dextromethorphan/105 mg bupropion) once daily in the morning for 3 days, then increase to one tablet twice daily (separated by at least 8 hours) as the maintenance dose. 1

Standard Dosing Protocol

• Days 1-3: One tablet once daily in the morning 1
• Day 4 onward: One tablet twice daily, with doses separated by at least 8 hours 1
• Administration: Swallow tablets whole with or without food; do not crush, divide, or chew 1
• Maximum: Do not exceed two doses within the same day 1

Dose Modifications

Reduce to one tablet once daily in the morning for: 1

• Moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) 1
• Concomitant use with strong CYP2D6 inhibitors 1
• Known CYP2D6 poor metabolizers 1

Pre-Treatment Screening Requirements

Before initiating Auvelity, you must: 1

• Assess blood pressure and monitor periodically during treatment, as Auvelity can cause hypertension 1
• Screen for personal or family history of bipolar disorder, mania, or hypomania to avoid precipitating manic episodes 1
• Verify the patient is not taking other medications containing bupropion or dextromethorphan to prevent overdose and seizure risk 1
• Confirm no seizure disorder, current/prior bulimia or anorexia nervosa (absolute contraindications) 1
• Ensure no concurrent MAOI use or within 14 days of MAOI discontinuation 1

Monitoring Protocol

Begin monitoring within 1-2 weeks of initiation and continue regularly: 2

• Suicidal thoughts and behaviors: Highest risk occurs during the first 1-2 months of treatment, particularly in patients under age 24 2, 1
• Emergence of agitation, irritability, or unusual behavioral changes indicating worsening depression 2
• Blood pressure: Monitor periodically throughout treatment 1
• Therapeutic response: Assess depressive symptom improvement using standardized scales 2

Response Assessment Timeline

Auvelity demonstrates rapid onset of action compared to traditional antidepressants: 3, 4

• Week 1: Significant improvement in depression scores observed as early as 1 week post-initiation 3, 4
• Week 2: Continued significant improvement with higher remission rates than comparators 3, 4
• Week 6: Primary endpoint assessment showing sustained efficacy 3

If inadequate response by 6-8 weeks, modify treatment strategy per general MDD guidelines 2

Clinical Context for Use

Auvelity is indicated for adults with MDD who have not responded to other antidepressants, though it can also be used as first-line therapy. 1, 5

Evidence for Treatment-Resistant Depression

• In real-world practice, 83.7% of patients initiating Auvelity had prior treatment with SSRIs, SNRIs, or bupropion monotherapy 6
• 71.2% of patients used Auvelity as add-on therapy to existing antidepressants, most commonly added to SSRIs (10.7%) or SNRIs (6.5%) 6
• 28.8% initiated as monotherapy, and 10.1% were treatment-naïve 6

Efficacy Data

Phase 3 trial (GEMINI) demonstrated: 3

• Mean MADRS score reduction of -15.9 points vs -12.0 points with placebo at week 6 (difference -3.87, p=0.002) 3
• Remission rate of 39.5% vs 17.3% with placebo (difference 22.2%, p<0.001) 3
• Response rate of 54.0% vs 34.0% with placebo (difference 20.0%, p<0.001) 3
• Significant improvement as early as week 1 (p=0.007) 3

Phase 2 trial vs bupropion monotherapy showed: 4

• Greater MADRS reduction over weeks 1-6 (-13.7 vs -8.8 points, p<0.001) 4
• Remission rate of 46.5% vs 16.2% at week 6 (p<0.001) 4
• Response rate of 60.5% vs 40.5% at week 6 4

Safety Profile and Common Adverse Events

Most common adverse events are mild-to-moderate: 7, 3

• Dizziness, nausea, headache, somnolence, and dry mouth 3
• Decreased appetite and anxiety 4
• Not associated with psychotomimetic effects, weight gain, or increased sexual dysfunction 3, 4

Critical Safety Warnings

Absolute contraindications: 1

• Seizure disorder (bupropion lowers seizure threshold) 1
• Current or prior bulimia or anorexia nervosa (higher seizure incidence) 1
• Concurrent MAOI use or within 14 days of MAOI discontinuation (risk of hypertensive crisis and serotonin syndrome) 1
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs (increased seizure risk) 1

Duration of Treatment

Once adequate response is achieved: 2

• Continue treatment for 4-9 months after satisfactory response for first episode MDD 2
• For patients with 2 or more prior episodes, longer duration therapy (years to lifelong) may be beneficial 2
• Long-term open-label studies showed maintained efficacy through 12-15 months with remission rates approaching 70% 7

Mechanism of Action Rationale

Auvelity's unique dual mechanism targets glutamatergic dysfunction in depression: 5, 7

• Dextromethorphan acts as an NMDA receptor antagonist and sigma-1 receptor agonist 5, 7
• Bupropion inhibits CYP2D6, increasing dextromethorphan bioavailability by preventing rapid metabolism 5, 7
• This combination addresses altered glutamatergic neurotransmission implicated in MDD pathogenesis 8, 3